Use of preoperative erythropoietin therapy to facilitate autologous blood donation in orthopedic surgery

A meta-analysis

Xiao Chang, MD, Qiyi Li, MD*, Huang Tang, MM

Abstract

Background: Autologous blood transfusion helps to avoid or reduce the need for allogenic blood transfusion in patients undergoing major surgery. We examined the value of erythropoietin therapy to support preoperative autologous blood donation (PABD) in patients undergoing orthopedic surgery.

Methods: For this systematic review and meta-analysis, Medline, Cochrane, EMBASE, and Google Scholar databases were searched from October 26th, 1989 until September 30th, 2017. Primary outcomes were percentages of patients able to donate ≥4 units of blood for autologous transfusion, amount of allogenic blood transfused, changes in hematocrit and hemoglobin levels from before PABD to immediately before surgery, and adverse events.

Results: Of 256 studies identified, 18 studies met the inclusion criteria with a total of 1914 patients (mean age 51–69 years), of whom 1153 were treated with erythropoietin. Erythropoietin was associated with a greater percentage of patients able to donate ≥4 units of blood for autologous use compared to controls (OR = 6.00, 95% CI = 3.97 to 9.09, P < .001). Patients receiving preoperative erythropoietin had significantly less of a reduction in hematocrit and hemoglobin levels from before PABD to immediately before surgery compared with controls (hematocrit: mean differences = −1.438, 95% CI = −2.14 to −0.73, P < .001; hemoglobin: mean differences = −1.426, 95% CI = −1.78 to −1.07, P < .001). No significant differences were observed in the amount of allogenic blood transfused between patients receiving erythropoietin and controls (difference in means = −0.220, 95% CI = −0.536 to 0.097, P = .174). Patients who received erythropoietin were less likely to experience dizziness than controls, but the incidence of nausea or fatigue were similar between groups.

Conclusion: Erythropoietin therapy during the PABD period results in less of a reduction in hematocrit and hemoglobin levels and an increase in the percentage of patients able to donate blood preoperatively.

Abbreviations: 95% CI = 95% confidence intervals, ABT = allogenic blood transfusions, AE = adverse event, EAS = erythropoiesis-stimulating agent, OR = odds ratio, PABD = preoperative autologous blood donation, RBC = red blood cell, RCT = randomized controlled trial, rHuEPO = recombinant human erythropoietin.

Keywords: autologous blood donation, erythropoietin, orthopedic surgery, transfusion

1. Introduction

Allogeneic blood transfusions (ABT) are often necessary in major orthopedic surgery such as hip replacement and complex spine procedures because of perioperative blood loss. While donor screening and advances in blood testing have reduced risk of ABT-carried infection, ABT is still associated with other risks, including transfusion reactions, allo-immunization, and transfusion-related immunomodulation that may increase the risk of infection in the postoperative period.[1]
Autologous blood transfusion has become an important method by which to avoid or reduce the need for ABT in patients undergoing major surgery when significant blood loss is expected and transfusion is likely. Autologous blood transfusion typically involves preoperative autologous blood donation (PABD) by the patient and then reinfusion of the patient’s own blood during surgery. The amount of PABD, however, is limited by the body’s ability to replenish the blood withdrawn from circulation. Study has shown that the body’s endogenous erythropoietin response to autologous blood donation is not sufficient to stimulate maximal erythropoiesis in the marrow. The availability of iron has also been shown to be a limiting factor in red blood cell (RBC) production after phlebotomy.

Erythropoietin, a hormone that stimulates erythropoiesis, was discovered in 1953 and recombinant human erythropoietin (rHuEPO) was developed in the 1980s. Erythropoietin is widely used to treat anemia in patients with chronic renal failure. It is also used for correcting anemia in patients who undergo PABD. A previously published study showed that patients undergoing PABD who were treated with rHuEPO were able to donate a higher RBC volume than patients who received placebo. Though the use of PABD is increasing, concerns remain such as donor anemia, wastage of donated autologous blood, a lower transfusion threshold, and indications that autologous donors are more likely to require perioperative blood transfusions than those who do not undergo PABD.

A prior systematic review concluded that currently available evidence is insufficient to stimulate maximal erythropoiesis in the marrow. The purpose of the current study was to perform a systematic review and meta-analysis to determine whether preoperative erythropoietin therapy increased the percentage of patients able to give ≥4 units of blood for autologous transfusion before surgery and decrease the amount of allogeneic blood transfused. Safety was also assessed.

2. Materials and methods

2.1. Literature search strategy

This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines [19] Medline, Cochrane, EMBASE, and Google Scholar databases were searched from October 26th, 1989 until September 30th, 2017 using combinations of the following search terms: autologous blood transfusion, erythropoietin, and orthopedic surgery, as follows: (orthopedic AND (autologous OR blood OR transfusion)) AND erythropoietin. Reference lists of relevant studies were hand-searched. Patients’ raw data and private information were not required nor were used in the present study, and thus approval from the institutional review board and patients’ informed consent were waived.

2.2. Selection criteria and data extraction

Inclusion criteria were:

1) Randomized controlled trials (RCTs);
2) Patients received orthopedic surgery and underwent PABD;
3) Comparisons between patients who received preoperative erythropoietin and those who did not receive erythropoietin (control group);
4) Quantitative outcome data of hemoglobin or hematocrit levels during the preoperative, perioperative, and postoperative periods;
5) Published in English or Chinese. Cohort studies, letters, comments, editorials, case reports, proceedings, personal communications and retrospective studies were excluded.

Studies that included patients who received anticoagulants, who had congenital anemia/thalassemia, or who were not eligible for erythropoietin therapy were further excluded. Studies were also excluded if the variables of interest were not reported or presented quantitatively. Studies were identified by the above search strategy by two independent reviewers. Where there was uncertainty regarding eligibility, a third reviewer was consulted.

From studies that met the inclusion above selection criteria, the following information/data were extracted: the name of the first author, year of publication, number of participants in each group, participants’ age and gender, intervention protocol, mean unit blood collected per patient, percentage of patients able to donate ≥4 units of blood for autologous use, as previously described, hematocrit/hemoglobin level before PABD and immediately before surgery, the amount of allogeneic blood transfused and adverse events (AEs).

2.3. Quality assessment

The methodological quality of each study was assessed using the risk-of-bias assessment tool outlined in the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0) [20] by 2 reviewers.

2.4. Outcome measures and data analysis

The outcomes included the percentage of patients able to donate ≥4 units of blood for autologous transfusion, as previously described; amount of allogeneic blood transfused; changes in hematocrit and hemoglobin levels from PABD to immediately before surgery; and occurrence of adverse events. Outcomes were compared between the erythropoietin-treated PABD and PABD alone (control) groups. For amount of allogeneic blood transfused and hematocrit/hemoglobin change from PABD to immediately before surgery, means with standard deviations were calculated and compared between the 2 groups; the combined effect size, difference in means between groups with 95% confidence intervals (95% CI) were calculated for each individual study, and for the studies combined. For percentage of patients able to donate ≥4 units of blood for autologous transfusion and the occurrence of AEs, the rates were summarized for each group; the combined effect size, odds ratios (ORs) with 95% CI were calculated for each individual study and for the studies combined. A y2-based test of homogeneity was performed, and the inconsistency index (I2) and Q statistics were determined. For the Q statistic, P < .10 was considered to indicate statistically significant heterogeneity. The I2 statistic indicates the percentage of the observed between-study variability caused by heterogeneity, and a value >50% was established as indicating significant heterogeneity. If heterogeneity existed between studies (a Q statistic with P < .1 or an I2 statistic >50%), a random-effects model (DerSimonian-Laird method) of analysis was used. Otherwise, a fixed-effect model was used (Mantel-Haenszel method). Pooled effects were
calculated, and a 2-sided $P$ value $< .05$ was established as statistical significance. Sensitivity analysis was carried out using the leave one-out approach. Publication bias was not assessed for $<10$ studies because $>10$ studies are required to detect funnel plot asymmetry. All analyses were performed using Comprehensive Meta-Analysis statistical software, version 2.0 (Biostat, Englewood, NJ).

3. Results

3.1. Literature search results and study characteristics

A flow diagram of study selection is shown in Figure 1. A total of 256 studies were identified by the database searches. After removal of duplicates and non-relevant studies as determined by title and abstract review, 56 studies were fully reviewed for eligibility. Thirty-eight studies were deemed ineligible due to control group design (13 studies), reported outcomes (12 studies), study type (6 studies), duplicate trials (2 studies), publication language (3 studies), and publication type (2 studies).

Eighteen studies with a total of 1914 patients were included in the meta-analysis (Table 1) [10,13,25–40] All included studies were RCTs. Overall, 1153 patients were treated with erythropoietin and 761 were not. Patients’ mean age across studies was 60 years, ranging from 51 to 69 years. Patients received hip or knee replacement, or spine surgeries, including laminectomy. The protocols for administering erythropoietin varied considerably between the studies, but the drug was typically given for 3 to 4 weeks before surgery and during the period of PABD. In all protocols, oral iron was given but, as with erythropoietin, the dosage varied between studies. A summary of outcomes, including baseline and preoperative hemoglobin and hematocrit levels of the included studies are shown in Table 2.

3.2. Percentage of patients able to donate $\geq 4$ units of blood for autologous use

Six studies [27,30,35–38] that reported the percentage of patients able to donate $\geq 4$ units of blood for autologous use were included for analysis. No evidence of heterogeneity ($I^2 = 0\%$, $Q$ statistic = 3.677, $P = .597$) was found, thus a fixed-effects model was used. The combined effect indicated that the erythropoietin group had a higher percentage of patients being able to donate $\geq 4$ units of blood for autologous use compared to that in the control group (OR = 6.00, 95\% CI = 3.97 to 9.09, $P < .001$) (Fig. 2).

3.3. Changes in hematocrit and hemoglobin levels from before PABD to immediately before surgery

Only 2 studies, Adamson et al [27] and Mercuriali et al [28] reported complete data for hematocrit, while another 2 studies, Beris et al [40] and Schlaeppi et al [29] reported full outcomes for hemoglobin. These four studies were used in the analysis. A fixed-effects model was applied for both outcomes because no evidence of heterogeneity was found (hematocrit: $I^2 = 0\%$, $Q$ statistic = 0.932, $P = .334$; hemoglobin: $I^2 = 0\%$, $Q$ statistic = 0.004, $P = .949$). The combined effect indicated that the erythropoietin group had less of a reduction in hematocrit and hemoglobin levels after PABD compared to levels in the control group (hematocrit: difference in means = 1.438, 95\% CI = 0.73 to 2.14, $P < .001$;
## Table 1
Characteristics of the studies included in the meta-analysis.

| First author (year) | Group | Number of patients | Age (year) | Male (%) | Erythropoietin dose/ frequency | Iron supplement | PABD protocol | Mean unit blood collected per patient |
|---------------------|-------|--------------------|------------|----------|-------------------------------|----------------|--------------|--------------------------------------|
| Sharma (2013)       | Placebo | 35                | 52*        | 69       | 15,000 IU (average 200 IU/kg) rHu-EPO i.v. twice a week | Ferrous sulphate 3 x 65 mg | Hb level ≤ 80 g/L and/or clinical symptoms of anaemia (increased heart rate or lower blood pressure despite fluid i.v. bolus) | 3.05±0.71 |
|                     | EPO    | 30                | NR         | NR       | 30,000 IU (average 400 IU/kg) rHu-EPO i.v. once a week |                |                      | 4.33±0.4 |
|                     | Weber Erythropoietin (2012) | 47       | 67         | 10       | 40,000 IU Epoetin-α subcutaneously once weekly for 3 weeks before surgery and/or on the day of surgery | Oral iron daily for 3 weeks. Blood transfusions were only given according to an Hb-based transfusion trigger, as described in the hospital transfusion protocol. |                      | |
|                     | Control | 237               | 67         | 11       | 40,000 units Epoetin-α subcutaneously weekly for 4 wk. | Ferrous sulphate 325 mg 3 times a day | HCT < 24 asymptomatic, HCT < 30 with symptoms | |
|                     | Shapiro (2005) | 25                | 51         | 20       | 6000 IU i.v. twice weekly for 3 weeks | Ferrous sulphate 105 mg/day; p.o. for 1 month before and after surgery. |                      | |
|                     | Placebo (2005) | 23               | 53±13      | 17       | 6000 IU i.v. twice weekly for 3 weeks |                |                      | 4.5±1.0 |
|                     | Hasegawa (1999) | 17                | 46±16      | 0        | untreated | Iron saccharate 200 mg during each treatment visit |                      | 3.0±1.1 |
|                     | Mercuriali Epoetinalla 75 IU/kg (1998) | 9                 | 63.5±8.5   | 1        | 75 IU/kg i.v. |                      |                      | 4.5±1.0 |
|                     | Epoetinalla 150 IU/kg | 10               | 59.2±11.2  | 0        | 150 IU/kg i.v. |                      |                      | 3.0±1.1 |
|                     | Epoetinalla 300 IU/kg | 10               | 61.0±4.5   | 0        | 300 IU/kg |                      |                      | 4.5±1.0 |
|                     | Placebo | 9                 | 64.6±7.7   | 2        |                |                      |                      | 3.0±1.1 |
|                     | Goodnough Epoetinalla (1997) | 4                | 63.5±7.7   | NR       | 6000 IU/kg i.v. |                      |                      | 4.5±1.0 |
|                     | EPO (RA patients) | 32               | 60.7±17    | 17       | 6000 IU/kg i.v. |                      |                      | 3.0±1.1 |
|                     | Placebo (RA patients) | 6                | 62.2±10.6  | 3        |                |                      |                      | 4.5±1.0 |
|                     | Placebo (non-RA patients) | 28               | 60.1±14    | 17       |                |                      |                      | 3.0±1.1 |
|                     | Adamson Epoetinalla (1996) | 86               | 600 IU/kg twice a week for 3 wks; i.v. | untreated | Iron saccharate 325 mg 3 times daily (approximately 180 mg elemental iron) 200 mg elemental iron patients were transfused if Hct level was ≤32% |                      | |
|                     | Placebo | 87                | NR         | NR       | oral ferrous sulphate 325 mg |                      |                      | 3.0±1.1 |
|                     | Nydegger EPO (1996) | 19               | NR         | NR       | 100 IU/kg sc | Oral ferrous sulphate 150 mg once daily |                      | 4.5±1.0 |
|                     | Placebo | 86                | 62±15      | 11       | 600 IU/kg |                      |                      | 3.0±1.1 |
|                     | Price Placebo (1996) | 86               | 61±17      | 11       | 600 IU/kg |                      |                      | 4.5±1.0 |
|                     | Sans Erythropoietin (1996) | 11            | 67         | 55       | 100 IU/kg rhEPO sc twice a week | Iron saccharate 270 mg orally twice daily | Patient receiving hip or knee replacement for whom ≥ 3 units of blood was requested | 3.3±1.0 |
|                     | Placebo (1996) | 13                | 69         | 54       | rhEPO | Iron saccharate 200 mg i.v. twice a week for 3 weeks; sc |                      | 3.9±0.7 |
|                     | Tryba Epoetinalla 50 + i.v. iron (1996) | 125              | 60±15      | 11       | Epoetin-alfa 50 IU/kg twice a week for 3 weeks; sc | Iron saccharate 200 mg i.v. twice a week for 3 weeks | 1 unit of AB (450 ml) was donated at each of the six preoperative visits if Hct ≥ 34% | 4.3 |
|                     | Epoetinalla 100 + i.v. iron (1996) | 125              | 60±15      | 11       | Epoetin-alfa 100 IU/kg twice a week for 3 weeks; sc | Iron saccharate 200 mg i.v. twice a week for 3 weeks |                      | 4.5 |
|                     | Epoetinalla 150 + i.v. iron (1996) | 125              | 60±15      | 11       | Epoetin-alfa 150 IU/kg twice a week for 3 weeks; sc | Iron saccharate 200 mg i.v. twice a week for 3 weeks |                      | 4.6 |
|                     | Untreated control i.v. iron only (1996) | 125              | 60±15      | 11       | Epoetin-alfa 200 IU/kg twice a week for 3 weeks; sc | Iron saccharate 200 mg i.v. twice a week for 3 weeks |                      | 3.8 |
|                     | Goodnough Erythropoietin (1996) | 18               | NR         | NR       |                |                    |                      | 4.6±1.1 |

(continued)
hemoglobin: difference in means $=-1.426, 95\% \text{ CI} = -1.78 \text{ to } -1.07, P<.001$) (Fig. 3).

### 3.4. Amount of allogeneic blood transfused

Five studies, Bujan,[10] Goodnough,[36] Goodnough,[26] Goodnough,[37] and Mercuriali,[32] reported the amount of allogeneic blood transfused. A random effects model was applied due to the presence of heterogeneity in the data ($I^2 = 63.23\%$, Q statistic $= 10.878, P = .028$). No differences in the amount of allogenic blood transfused were observed between the 2 groups (difference in means $=-0.220, 95\% \text{ CI} = -0.536 \text{ to } 0.097, P = .174$) (Fig. 4).

### 3.5. Adverse events

The commonly encountered AEs of nausea, fatigue, and dizziness were analyzed individually. Only perioperative in-hospital AEs were included; long-term sequelae of the intervention were not evaluated. Three studies reported data of nausea,[13,37,39] and a fixed-effects model was used as there was no evidence of heterogeneity ($I^2 = 0\%$, Q statistic $= 1.714, P = .424$). Analysis revealed no significant differences in the incidence of nausea between the erythropoietin and control groups (pooled OR $= 1.12, 95\% \text{ CI} : 0.45 \text{ to } 2.76, P = .807$, Fig. 5A).

Two studies reported data of fatigue.[13,36] Moderate heterogeneity was found in the data ($I^2 = 53.5\%$, Q statistic $= 2.15, P = .143$), thus a random-effects model was used. Analysis revealed no significant differences in the incidence of fatigue between the two groups (pooled OR $= 1.27, 95\% \text{ CI} : 0.20 \text{ to } 7.99, P = .800$, Fig. 5B).

Four studies reported data of dizziness.[13,36,37,39] No significant heterogeneity was present in the data ($I^2 = 0\%$, Q statistic $= 1.368, P = .713$), thus a fixed-effects model was used. Analysis revealed that patients treated with erythropoietin were less likely to experience dizziness compared with those who did not receive the drug (pooled OR $= 0.39, 95\% \text{ CI} : 0.18 \text{ to } 0.83, P = .014$, Fig. 5C).

### 3.6. Sensitivity analysis

Sensitivity analysis was performed using the leave-one-out approach for the percentage of patients able to donate ≥4 units of blood for autologous use and amount of allogenic blood transfused (Supplemental Fig. 1, http://links.lww.com/MD/D573). The direction and magnitude of combined estimates did not vary markedly with the removal of individual studies, indicating that the meta-analysis had good reliability and the data were not overly influenced by any single study.

### 3.7. Quality assessment

Results of the quality assessment of the included studies are shown in Supplemental Figure 2, http://links.lww.com/MD/D574. Overall, an unclear or high risk of bias was present for 16 of the studies that did not include an intent-to-treat analysis. In >50% of the studies, it was unclear or a high risk of performance bias (blinding of participants or personnel) and/or detection bias (blinding of outcome assessment) was noted. Overall the included articles were of adequate quality.

### 4. Discussion

The present review evaluated the impact of erythropoietin on improving the ability of patients to donate autologous blood

| First author (year) | Group | Number. of patients | Age (year) | Male (%) | Erythropoietin dose/ frequency | Iron supplement | PABD protocol | Mean unit blood collected per patient |
|---------------------|-------|---------------------|------------|----------|-------------------------------|----------------|----------------|------------------------------------|
| (1994) Schiegg       | Placebo | 23                  | 64.0±6.7 | 10       | 0.000 IU/kg given three times per week | Oral iron supplement 325 mg 3 times a day | Effective orthopedic surgical protocol requiring ≥2 units Minimum age: 12 years | 5.6±0.8 |
| (1994) Mercuriali     | Placebo | 9                   | 55 (30–60) | 0        | 0.000 IU/kg given three times per week | Oral iron supplement 325 mg 3 times a day | Effective orthopedic surgical protocol requiring ≥2 units Minimum age: 12 years | 5.6±0.8 |
| (1990) Goodnough     | Placebo | 5                   | 41.3±24.3 | 2        | 0.000 IU/kg given three times per week | Oral iron supplement 325 mg 3 times a day | Effective orthopedic surgical protocol requiring ≥2 units Minimum age: 12 years | 5.6±0.8 |
| (1993) Bujan         | Placebo | 9                   | 64.8±8.3 | 14       | 0.000 IU/kg given three times per week | Oral iron supplement 325 mg 3 times a day | Effective orthopedic surgical protocol requiring ≥2 units Minimum age: 12 years | 5.6±0.8 |
| (1992) Rivas         | Placebo | 5                   | 64.8±8.3 | 14       | 0.000 IU/kg given three times per week | Oral iron supplement 325 mg 3 times a day | Effective orthopedic surgical protocol requiring ≥2 units Minimum age: 12 years | 5.6±0.8 |

Hb = hemoglobin; HCT = hematocrit; i.v. = intravenous; NR = not response; rHuEPO = recombinant human erythropoietin; sc = subcutaneous; SE = standard error.
| First author | Group | Number of patients | % of patients able to donate >= 4 units of blood for autologous use | Hematocrit (%) | Hemoglobin | Adverse Events (%) |
|--------------|-------|--------------------|---------------------------------------------------------------|----------------|------------|-------------------|
| Sharma       | Erythropoietin | 33 | 0.1±0.4 unit/pts | 37.18 | 122.37 (g/L) | Nausea: 9, Fatigue: 6, Dizziness: 9 |
| Bilian       | Placebo  | 35 | 0.23±0.49 unit/pts | 36.8 | 117 | 11 |
| Mercuriali   | EPO    | 31 | 0.12±0.51 unit/pts | 36.8 | 119 | 11 |
| Tryba        | Placebo | 21 | 0.2 unit/pts | 36.8 | 114.78 | 14.3±1.2 |
| Price        | EPO    | 9 | 0.4±0.8 unit/pts | 36.8 | 12.3±0.7 g/dL | 12.2±0.7 |
| Bartes       | Placebo | 52 | 0.6 unit/pts | 34.20 | 12.2±0.7 | 0.1 |
| Mercuriali   | rhEPO  | 19 | 0.12±0.14 unit/pts | 33.70 | 12.2±0.7 | 0.1 |
| Price        | Placebo | 9 | 0.12±0.14 unit/pts | 33.70 | 12.2±0.7 | 0.1 |
| Tryba        | Placebo | 52 | 0.6 unit/pts | 34.20 | 12.2±0.7 | 0.1 |
| Price        | Placebo | 9 | 0.12±0.14 unit/pts | 33.70 | 12.2±0.7 | 0.1 |

NR = non-response; pts = patients.
Figure 2. Meta-analysis of percentage of patients able to donate ≥4 units of blood for autologous transfusion. CI = confidence intervals.

Figure 3. Meta-analysis of changes in hematocrit and hemoglobin from before PABD to immediately before surgery. CI = confidence intervals.

Figure 4. Meta-analysis of amount of allogeneic blood transfused. CI = confidence intervals.
prior to orthopedic surgery and thereby help to reduce patients’ need for ABT peri- or postoperatively. In 18 studies with a total of 1153 patients, our meta-analysis revealed that erythropoietin therapy was associated with a greater percentage of patients able to donate ≥4 units of blood preoperatively and less of a reduction in patients’ hematocrit and hemoglobin levels following PABD compared to controls. The amount of allogenic blood transfused and the incidence of nausea and fatigue were similar between erythropoietin and control groups. Although a greater percentage of control patients experienced dizziness compared with erythropoietin treated patients, the results were not significant. These results suggest that erythropoietin therapy does not significantly reduce the need for ABT or related incidence of AEs.

Erythropoietin has been used to increase the hematocrit level in patients undergoing PABD prior to surgery. It is also given in patients not providing autologous blood prior to surgery so as to possibly reduce the need for allogenic blood transfusions. Results of the present meta-analysis are consistent with prior findings suggesting that the use of erythropoietin does not significantly reduce the need for ABT in patients undergoing orthopedic surgery. A recent review by Cherian et al[41] of preoperative blood management strategies for total hip arthroplasty, including preoperative iron therapy, intravenous erythropoietin, and autologous blood donation, concluded that no single strategy was superior to another in reducing the need for allogenic transfusions; however, the authors suggested that a combinational approach may result in improved blood loss outcomes. In a report not included in the present analysis, Deutsch et al[42] randomized patients undergoing primary total knee arthroplasty to receive either epoetin-α 40,000 U at preoperative days 14 and 7 or a standard PABD protocol, and baseline hematologic parameters were similar between the groups. In that study, by the day of surgery, the erythropoietin group had significantly higher hemoglobin/hematocrit levels and reticulocyte counts compared

Figure 5. Meta-analysis of adverse events of (A) nausea, (B) fatigue, and (C) dizziness.
to controls, and the differences remained significant for 1 to 2 days postoperatively. However, those authors found no significant differences in the incidence of allogeneic transfusions between groups, comparable to results of the present study.

In contrast, a meta-analysis conducted by Alsaleh et al. [43] pooled the results from 26 studies with 3560 patients undergoing knee or hip arthroplasty to evaluate the effectiveness of erythropoiesis-stimulating agents (ESAs, including erythropoietin) on reducing ABT and maintaining hemoglobin levels. That study found that the use of preoperative ESAs reduced the need for ABT, and a significant difference was found in mean hemoglobin between the ESA and control groups postoperatively. A more recent meta-analysis performed in 2016 by Zhao et al. [44] evaluated the preoperative use of erythropoietin in reducing ABT and complications in patients scheduled for total hip or knee arthroplasty. Those authors found that preoperative use of erythropoietin was associated with lower exposure to ABT and higher postoperative hemoglobin concentrations. A systematic review by Lin et al. [18] also found that erythropoietin reduced the need for ABT in patients from four RCTs. Those authors found that a short preoperative erythropoietin regimen or a single dose of erythropoietin plus IV iron in the pre-or peri-operative period reduced allogeneic transfusion rates (the number of patients needed to treat to avoid any transfusion ranged from 3 to 6).

Although no significant differences were observed in complications between patients who did or did not receive erythropoietin, Zhao et al. [44] did suggest that venous thromboembolism (VTE) was a major concern associated with erythropoietin therapy and, although some patients in that study treated with and without erythropoietin. Also, Alsaleh et al. [43] found no increased risk of thromboembolism in the ESA group compared with the control group. In contrast, other authors reported that erythropoietin was likely to increase the risk of thromboembolism in spine surgery patients who received only mechanical anti-thrombosis prophylaxis. [18]

In the present review, VTE was not evaluated as an endpoint, given the studies included did not provide such data.

Cost-effectiveness is important considerations in blood management strategies. On the cost side, several studies evaluated the advantages of erythropoietin in treating patients. Based on data from a German hospital, Toczekowski et al. [45] concluded that erythropoietin reduced ABT and associated complications in anemic patients undergoing elective hip or knee surgery, and thus was considered cost effective by a cost analysis model. Green et al. [46] found that preoperative erythropoietin was significantly less costly than ABT using a cost minimization analysis, and savings of $800 per patient undergoing total hip arthroplasty and $392 per patient undergoing total knee arthroplasty could be realized through administering preventive erythropoietin. In contrast, the studies of Coyle et al. [47] and Bedair et al. [48] concluded that the use of erythropoietin was not cost-effective, even though it reduced ABT. Despite these findings, results of the present review and others still report that preventive use of erythropoietin is not associated with substantial reduction in peri-operative allogeneic blood transfusion, and thus estimating cost benefits may not be relevant.

### 4.1. Limitations

Several important limitations of the present analysis must be considered. Marked variation was present among the studies with respect to the dosage and administration of erythropoietin and blood transfusion protocols. Although 18 studies were included in the present study, only a few studies contributed to the individual subsections of meta-analysis. For example, while 11 studies reported allogeneic blood transfused, only 5 studies provided all variables of interest and only two studies were included for evaluating changes in hematocrit or hemoglobin from pre-PABD to postoperative status. In addition, most studies were performed in the 1990’s. Only perioperative in-hospital AEs were reviewed. We did not evaluate the possible long-term AEs linked to erythropoietin therapy. For example, tumor growth is previously reported to be accelerated by EPO therapy. [49, 50] Nevertheless, the results of the present review must be interpreted with caution since adequately powered studies focusing on this topic are currently lacking. A lack of relevant studies in the medical literature clearly indicates that further research on the value of erythropoietin therapy in preparing for orthopedic surgery is highly warranted.

### 5. Conclusions

The use of erythropoietin prior to PABD results in less of a reduction in hemoglobin and hematocrit levels in patients undergoing orthopedic surgical procedures and a greater proportion of patients being able to donate blood preoperatively. However, erythropoietin administration does not appear to be associated with reductions in the use of ABT or the incidence of AEs.

### Author contributions

Conceptualization: Qiyi Li.

Data curation: Xiao Chang, Huang Tang.

Formal analysis: Qiyi Li, Huang Tang.

Writing – original draft: Huang Tang.

Writing – review & editing: Xiao Chang, Qiyi Li, Huang Tang.

### References

1. Hart S, Cserti-Gazdewich CM, McCluskey SA. Red cell transfusion and the immune system. Anaesthesia 2015;70(Suppl 1):38–43. e13-36.
2. Goodnough LT, Shander A. Current status of pharmacologic therapies in patient blood management. Anesth Analg 2013;116:13–24.
3. García-Erce JA, Muñoz M, Bisbe E, et al. Predeposit autologous donation in spinal surgery: a multicentre study. Eur Spine J 2004;13(Suppl 1):S34–9.
4. Kickler TS, Spivak JL. Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors. JAMA 1988;260:65–7.
5. Goodnough LT, Brittenham GM. Limitations of the erythropoietic response to serial phlebotomy: implications for autologous blood donor programs. J Lab Clin Med 1990;115:28–35.
6. Chaplin H Jr, Mallison PL. Red cell life-span in nephritis and in hepatic cirrhosis. Clin Sci 1953;13:351–60.
7. Weisbach V, Skoda P, Rippel R, et al. Oral or intravenous iron as an adjuvant to autologous blood donation in elective surgery: a randomized, controlled study. Transfusion 1999;39:465–72.
8. Boye C, Baudoux E, Salmon JP, et al. Increased iron absorption during autologous blood donation supported by recombinant human erythropoietin therapy. Transfusion 2006;46:1616–23.
9. Kennedy C, Leonard M, Devitt Ajr, et al. Efficacy of preoperative autologous blood donation for elective posterior lumbar spinal surgery. Spine (Phila Pa 1976) 2011;36:E1736–43.
10. Buljan M, Nemet D, Golubic-Cepulic B, et al. Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty. Int Orthop 2012;36:703–9.
[11] McGirr A, Pavenksi K, Sharma B, et al. Blood conservation in neurosurgery: erythropoietin and autologous donation. Can J Neurol Sci 2014;41:583–9.
[12] Weltert L, Rondinelli B, Bello R, et al. A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: results of a prospective single-blind randomized controlled trial. Transfusion 2015;55:1644–54.
[13] Sharma K, Sharma SB, Pukhta IA, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy in tertiary care hospitals of Jammu. Asian J Transfus Sci 2013;7:42–7.
[14] Forgie MA, Wells PS, Laupacis A, et al. Preoperative autologous donation decreases allogeneic transfusion but increases exposure to all red blood cell transfusion: results of a meta-analysis. International Study of Perioperative Transfusion (ISPOST) Investigators. Arch Intern Med 1998;158:610–6.
[15] Nuttall GA, Horlock TT, Santrach PJ, et al. Predictors of blood transfusions in spinal instrumentation and fusion surgery. Spine (Phila Pa 1976) 2000;25:596–601.
[16] Goldman M, Savard R, Long A, et al. Declining value of preoperative autologous donation. Transfusion 2002;42:819–23.
[17] Brook JF, Brown MD, Hentze SM, et al. Allogeneic transfusion after predonation of blood for elective spine surgery. Clin Orthop Relat Res 2008;466:1949–53.
[18] Lin DM, Lin ES, Tran MH. Efficacy and safety of intravenous iron in perioperative blood management: a systematic review. Transfus Med Rev 2013;27:221–34.
[19] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:838–45.
[20] Higgins JPT GS, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration 2011; http://www.cochrane-handbook.org.
[21] Vanderlinde ES. Autologous transfusion. BMJ 2002;324:772.
[22] Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820–6.
[23] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.
[24] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
[25] Hasegawa Y, Takamatsu J, Iwase T, et al. Effects of recombinant human erythropoietin on thrombosis and fibrinolysis in autologous transfusion for hip surgery. Arch Orthop Trauma Surg 1999;119:384–7.
[26] Goodnough LT, Marcus RE. The erythropoietic response to erythropoetin in patients with rheumatoid arthritis. J Lab Clin Med 1997;130:381–6.
[27] Adamson J, Epoetin alfa as an adjunct to autologous blood donation in patients with a low hematocrit scheduled for elective orthopedic surgery. Semin Hematol 1996;33(2 Suppl 2):15–6. discussion 17.
[28] Mercuriali F, Inghilleri G, Bifido FA, et al. Epoetin alfa in low hematocrit patients to facilitate autologous blood donation in total hip replacement: a randomized, double-blind, placebo-controlled, dose-ranging study. Acta Haematol 1998;100:69–76.
[29] Schlaeppe B, Gunter P, Nydegger UE. Enhancing the efficacy of preoperative autologous blood donation by erythropoietin. Transfus Sci 1994;13:171–7.
[30] Price TH, Goodnough LT, Vogler WR, et al. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion 1996;36:29–36.
[31] Weber EW, Slappendel R, Himon Y, et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: The European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005;22:249–57.
[32] Mercuriali F, Zanella A, Barosi G. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 1993;33:55–60.
[33] Tasaki T, Ohto H, Hashimoto C, et al. Recombinant human erythropoietin for autologous blood donation: effects on perioperative red-blood-cell and serum erythropoietin production. Lancet 1992;339:773–5.
[34] Nydegger U. Enhanced efficacy of autologous blood donation with epoetin alfa. Semin Hematol 1996;33(2 Suppl 2):39–40. discussion 41–32.
[35] Tryba M. Epoetin alfa plus autologous blood donation and normovolemic hemodilution in patients scheduled for orthopedic or vascular surgery. Semin Hematol 1996;33(2 Suppl 2):34–6. discussion 37–38.
[36] Goodnough LT, Rudnick S, Price TH, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 1989;321:1165–8.
[37] Goodnough LT, Price TH, Friedman KD, et al. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion 1994;34:66–71.
[38] Sans T, Boilf C, Joven J, et al. Effectiveness of very low doses of subcutaneous recombinant human erythropoietin in facilitating autologous blood donation before orthopedic surgery. Transfusion 1996;36:822–6.
[39] Shapiro GS, Roachie-Adjie O, Dhawlikar SH, et al. The use of Epoetin alfa in complex spine deformity surgery. Spine (Phila Pa 1976) 2002;27:2067–71.
[40] Beris P, Mermilod B, Levy G, et al. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. A prospective study. Vox Sang 1993;65:212–8.
[41] Cherian JJ, Kapadia BH, Issa K, et al. Preoperative blood management strategies for total hip arthroplasty. Surg Technol Int 2013;23:261–6.
[42] Deutsch A, Spaulding J, Marcus RE. Preoperative epoetin alpha vs autologous blood donation in primary total knee arthroplasty. J Arthroplasty 2006;21:628–35.
[43] Alsulile K, Alotaibi GS, Almadaimegh HS, et al. The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty; a meta-analysis of randomized controlled trials. J Arthroplasty 2013;28:1463–72.
[44] Zhao Y, Jiang C, Peng H, et al. The effectiveness and safety of preoperative use of erythropoietin in patients scheduled for total hip or knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials. J Arthroplasty 2013;28:1463–72.
[45] Tomezczkowski J, Stern S, Muller A, et al. Potential cost saving of Epoetin alfa in elective hip or knee surgery due to reduction in blood transfusions and their side effects: a discrete-event simulation model. PLoS One 2013;8:e72949.
[46] Green WS, Toy P, Bozic JK. Cost minimization analysis of preoperative erythropoietin vs autologous and allogeneic blood donation in total joint arthroplasty. J Arthroplasty 2010;25:93–6.
[47] Coyle D, Lee KM, Ferguson DA, et al. Economic analysis of erythropoietin use in orthopaedic surgery. Transfus Med 1999;9:21–10.
[48] Bedair H, Yang J, Dwyer MK, et al. Preoperative erythropoietin alpha reduces postoperative transfusions in THA and TKA but may not be cost-effective. Clin Orthop Relat Res 2015;473:590–6.
[49] Pradpe S. Erythropoietin stimulates tumor growth via EphB4. Cancer Cell 2015;28:610–22.
[50] Tankiewicz-Kwedlo A. Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and H-29 xenografts. Mol Cell Biochem 2016;421:1–8. doi: 10.1007/s11010-016-2779-x.